Drug developers have been acquiring complimentary programs to reduce execution risk and maintain investor interest.

CSL analysts reckon the healthcare giant is undervalued after Tuesday's market hiding, but remain bearish about a near-term ...

The ASX 200 was looking a little unsteady this morning, overloaded by a barrage of quarterlies as reporting season kicks off ...

If house prices keep rising at current rates, retiring with a mortgage will be commonplace, writes James Kirby.

Quarterly season is almost done, and David Franklyn joins to give his best and worst September gold performers, plus a ...

Macquarie Bank’s provision of funding for QPM Energy’s Issac Power Station is a sign that east coast plays could have more ...

The ASX was cruising early before a hotter-than-expected CPI smacked the rally. Meanwhile CSL was bruised again, but Boss ...

In this latest episode of Stockhead’s Who’s Who on the ASX, host Tylah Tully spotlights Codeifai (ASX:CDE). Codeifai offers ...

Wellness has gone to a trillion-dollar lifestyle, and EZZ Life Science is diving straight into America’s booming self-care ...

The former was weighed down by CSL (ASX:CSL) ’s guidance cut. CSL plunged 15% after slashing earnings guidance and shelving ...

Mount Ridley left the pack in its dust on Tuesday, clocking a 140% gain to take the lead in Australia’s gallium race.